Google NewsASX: ATH — Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise - Kalkine
ASX: ATH — Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise Kalkine
ALTERITY THERAP LTD ORDINARY (ATH) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXChange of Director's Interest Notice x 2
director_dealing announcement
Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434 - Kalkine
Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434 Kalkine
Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
other announcement
KalkineAlterity Reshapes Capital Structure as Phase 3 Ambitions Take Centre Stage
Highlights Alterity Therapeutics has commenced a share consolidation and introduced a temporary ASX ticker during the transition period. The move is designed to simplify the company's capital structure as it advances its lead neurodegenerative disease program. Market attention is increasingly focused on the company's preparations for a pivotal late-stage clinical trial. Alterity Therapeutics has streamlined its capital structure as it continues advancing its lead neurodegenerative disease pro...
Share Consolidation Effective, Trading Under ATHDA
other announcement
Alterity Therapeutics (ASX:ATH) Moves Toward Phase III Planning as MSA Research Gains Attention - Kalkine
Alterity Therapeutics (ASX:ATH) Moves Toward Phase III Planning as MSA Research Gains Attention Kalkine
StockheadAlterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning
Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development for Multiple ... Read More The post Alterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning appeared first on Stockhead.
Alterity Data Supports ATH434 Phase 3 Advancement in MSA
other announcement
Alterity strengthens ATH434 case with validated brain imaging biomarker in MSA
Alterity bioMUSE study shows advanced MRI imaging detects iron changes in the brain linked to diagnosis and severity in patients ... Read More The post Alterity strengthens ATH434 case with validated brain imaging biomarker in MSA appeared first on Stockhead.
Alterity Announces Publication on MRI as Biomarker for MSA
other announcement
Alterity to Deliver Presentations at May Medical Meetings
other announcement
Alterity Receives Positive FDA Feedback on CMC Meeting
other announcement
Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN
other announcement
StockTake: Alterity Therapeutics adds industry veteran to board
Alterity Therapeutics has appointed Ann Cunningham to the board as independent non-executive director role. ... Read More The post StockTake: Alterity Therapeutics adds industry veteran to board appeared first on Stockhead.
Alterity Appoints Biotech Executive Ann Cunningham to Board
other announcement
Alterity Announces Late-Breaker Oral Presentation at AAN
other announcement
Alterity to Host KOL Event to Share New Insights on ATH434
other announcement
Alterity gains positive FDA feedback ahead of phase III MSA trial
Alterity Therapeutics receives positive feedback following a Type C Meeting with the US Food and Drug Administration regarding its planned ... Read More The post Alterity gains positive FDA feedback ahead of phase III MSA trial appeared first on Stockhead.
Alterity Advances Toward Late-Stage Trial Pathway
Highlights Regulatory alignment strengthens development roadmap Lead therapy targets rare neurodegenerative condition Late-stage trial preparations gain momentum Alterity Therapeutics moves closer to a pivotal clinical phase after regulatory alignment, reinforcing its development strategy for a neurological treatment and advancing discussions around trial design and manufacturing readiness. A Step Forward in Clinical Development Alterity Therapeutics (ASX:ATH) has reached an important m...
Alterity Receives Positive FDA Feedback From Type C Meeting
other announcement
Alterity bolsters clinical expertise ahead of Phase III MSA trial
Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical expertise ahead of Phase III MSA trial appeared first on Stockhead.
Alterity to Participate in the Bell Potter Healthcare Summit
other announcement
Change of Director's Interest Notice - D Stamler
director_dealing announcement
Alterity to Present at the Bell Potter Healthcare Conference
other announcement
Alterity Presents Promising ATH434 Impact at AAS Symposium
other announcement